Evidence map›Paper›PMID 40697967›Full record

ArticleAdvances in radiation oncology2025

Comparative Analysis of

Hamed Bagheri, Seied Rabi Mahdavi, Parham Geramifar, Ali Neshasteh-Riz, Masoumeh Sajadi-Rad, Habibollah Dadgar, Hossein Arabi, Habib Zaidi

Abstract read
In one paragraph

Article in Advances in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hamed BagheriRadiation Biology Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Seied Rabi MahdaviDepartment of Medical Physics, Radiation Biology Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Parham GeramifarDepartment of Nuclear Medicine, School of Medicine, Shariati Hospital, Tehran, Iran.
Ali Neshasteh-RizRadiation Biology Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Masoumeh Sajadi-RadRadiation Biology Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Habibollah DadgarNuclear Medicine and Molecular Imaging Department, Imam Reza Research Center, RAZAVI Hospital, Mashhad, Iran.
Hossein ArabiDivision of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, Switzerland.
Habib ZaidiDivision of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Magnetic resonance imaging (MRI) with multiparametric assessment is a cornerstone in radiation therapy planning for primary prostate cancer (PCa), offering the potential for focal dose escalation to dominant intraprostatic lesions to enhance PCa management. The prostate-specific membrane antigen (PSMA), which is frequently overexpressed in PCa, has led to the development of Methods and Materials: A retrospective analysis was performed on 25 PCa patients who underwent Results: The average ± SD GTV-MRI and GTV-PET were 5.468 ± 11.6 cm³ and 11.136 ± 14.3 cm³, respectively, with the GTV-PET being significantly larger than the GTV-MRI ( Conclusions:

Identifiers

PMID40697967
PMCPMC12282173

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.